Category Archives: $VRTX

VRTX – one step closer to Approval for drug which treates the cause of Cystic Fibrosis…

2CentView tweeted this name back in June of 2014 when the stock popped from 65 to 90 on hopes a new drug which when used with an existing drug sold by Vertex could cure many more patients of this terrible disease which affects young children.

See below:

"Today’s positive recommendation brings the cystic fibrosis community one step closer to potential approval of the first medicine to treat the underlying cause of this disease for many more people," said Jeffrey Chodakewitz, M.D., Executive Vice President and Chief Medical Officer at Vertex. "We look forward to continuing to work with the FDA and other regulatory agencies throughout the world to make ORKAMBI available to eligible patients as soon as possible."

http://investors.vrtx.com/releasedetail.cfm?ReleaseID=912730

if you bought into the stock and hold a core or trading position – then HOLD a core position – and take profit in a trading position in the 135-140 area – but a keep a core position.

Stock has more upside from here when in the Summer final approvals – which should come barring any unforseen issues.

2CentView FV Now $120 on $VRTX – but this does not fully price in potential for new drug – which gives rea hope to sufferers of this terrible disease.

$VRTX (Vertex Pharma) Approaching $140 profit target as Biotechs surge

Vertex specializes the treatment of Cystic Fibrosis and have a drug called Kalydeco, which allows chloride to pass through cells – the problem is that the drug only works for specific Gene mutations, so limits the number of people that can benefit.

Tweeted this name back in June 2014 after it popped from 65 to 90 on positive data for a new drug which works alongside Kalydeco. It has been creeping higher since then.

Look to take some profit on the trade recommended in June.

Keep a core position if you like the company – stock is still not that expensiv on an implied 5Y growth of 16%.

$VRTX – Vertex Pharma – popped 40% – on hope new Cystic Fibrosis drug can treat another 28,000..

Vertex specializes the treatment of Cystic Fibrosis and have a drug called Kalydeco, which allows chloride to pass through cells – the problem is that the drug only works for specific Gene mutations, so limits the number of people that can benefit.

Positive Data for a new drug which works with Kalydeco was published yesterday, allowing the possibility of treating of up to 28,000 sufferers of the disease – at 160,000 a pop this equates to around 5billion dollars of incremental revenue.

FV of Vertex = 110, which is does not seem to be fully pricing in the potential for this new drug Lumacaftor, so the stock could go as high as 150, as earnings estimates have not been fully revised yet by Analysts.

Strategy: Buy here at 93, Target 140, stop 65. [93 assumes 50% 5Y Earnings growth]

VERY HIGH RISK – keep position small and be prepared to take the loss.

http://www.techinsider.net/vertex-pharmaceuticals-incorporated-vrtx-biggest-announcement-of-the-year-coming-says-meg-tirrell/116467.html